Six years and nearly $1B later, Boehringer Ingelheim's largest ever investment is now operational
Six years ago, Boehringer Ingelheim announced that a new manufacturing plant focused on large-scale cell culture technology would be erected in Vienna, marking the largest investment in the company’s history. Last week, the site became operational.
The site will add another 185,000 liters of production capacity and bring 500 new jobs to the area. Boehringer will produce its own product portfolio, as well as manufacture for third-party companies. The added capacity adds 30 percent to its mammalian large scale capacity and will allow easy changeover from one product to another.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.